Name
LSA2-L2
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for LSA2-L2
- Thioguanine
- Daunorubicin Hydrochloride
- Asparaginase
- Methotrexate
- Cytarabine
- Prednisone
- Cyclophosphamide
- Hydroxyurea
- Vincristine
- Carmustine
Name
Alternate Names
6-Mercaptoguanine
6-Thioguanine
Lanvis
Tabloid
Tioguanin
WR-1141
Abbreviations
6-TG
TG
TT-6
TT-G
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
752
000752
Primary Site
None
Histology
None
Remarks
A purine analogue antineoplastic agent; antimetabolite. FDA approved use for acute non-lymphocytic leukemia.
Coding
This drug should be coded
Name
Alternate Names
Acetyladriamycin
Cerubidine
Dauno-blastin
Daunomycin
Daunomycin-HCl
Daunorubicin
Daunorubicine
FI-6339
Leuk-aemomycin C
NDC-0082-4155
RP-13057
Rubidomycin
Rubidomycin HCl
Rubomycin C
Abbreviations
Daun
Dauno
DNM
DNR
DRB
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
082151
82151
Primary Site
Leukemia
Histology
None
Remarks
FDA approved use on ALL and ANLL; antitumor antibiotic
Coding
This drug should be coded
Name
Alternate Names
Asnase
Asparaginase (Escherichia coli)
Colaspase
Crasnitin#
EC3.1.5.1.
Elspar
Kidrolase
L-Asparaginase
Leunase (enzyme)
MK-965
Re-82-TAD-15
Abbreviations
ASP
ASPA
L-ASE
L-ASP
Category
Chemotherapy
Subcategory
Antineoplastic agent
NSC Number
109229
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039
Abbreviations
MTX
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
740
000740
Primary Site
Bladder cancer
Breast
Gestational trophoblastic cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Histology
None
Remarks
FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.
Coding
This drug should be coded
Name
Alternate Names
AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453
Abbreviations
ara-C
CA
HDA
HDARA-C
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
063878
63878
Primary Site
Histology
None
Remarks
Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)
Coding
This drug should be coded
Name
Alternate Names
Alti-Prednisone
Alto-Pred
Ancortone
Apo-Prednisone
Colisone
Cortan
Dacortin
Delta-Dome#
Deltasone
Deltra
Fernisone Buffered
Keysone
Liquid Pred
Meticorten
Novo-Prednisone
Orasone
Panasol
Paracort#
Prednicen M
SK-Prednisone
Sterapred DS
Ultracorten
Winpred
Abbreviations
PDN
PRD
PRED
Category
Hormones and hormonal mechanisms
Subcategory
Glucocorticoid
NSC Number
10023
010023
Primary Site
Histology
None
Remarks
Code Prednisone when it is part of a drug regimen.
Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.
Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.
Coding
Please see remarks for additional information
Name
Alternate Names
Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719
Abbreviations
CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
026271
26271
Primary Site
Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor
Histology
None
Remarks
An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent
Coding
This drug should be coded
Name
Alternate Names
Carbamo-hydroximic acid
Carbamohydroxamic acid
Carbamoyl oxime
Droxia
Hidrix
Hydrea
Hydreia
hydroxy-
Hydroxycarbamide
Hydroxycarbamine
Hydroxyl-urea
Hydura
Litaler
Litalir
Onco-Carbide
Oxyurea
SQ-1089
Urea
WR-83799
Abbreviations
HU
HUR
HYD
Category
Chemotherapy
Subcategory
Miscellaneous agent
NSC Number
032065
32065
Primary Site
Histology
None
Remarks
FDA approved uses on chronic myelogenous leukemia, head and neck cancers, melanoma, and advanced ovarian cancer.
Coding
This drug should be coded
Name
Alternate Names
Compound 37231
Leurocristine Sulfate
Oncovin
Vincasar
Vincasar PFS
Vincristine Sulfate
Vincrystine
Vinkristin
Abbreviations
LCR
VCR
VNCR
Category
Chemotherapy
Subcategory
Plant alkyloid--antimetabolite
NSC Number
067574
67574
Primary Site
None
Histology
None
Remarks
Antineoplastic; vinca plant alkaloid; antimetabolite. FDA approved uses in ALL, Hodgkin's lymphoma, non-Hodgkin's lymphoma, neuroblastoma, rhabomyosarcoma, and Wilm's tumor.
Coding
This drug should be coded
Name
Alternate Names
BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021
Abbreviations
BCNU
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
409962
Primary Site
Histology
None
Remarks
Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)
Coding
This drug should be coded